Compositions and methods of treating muscular dystrophy with thromboxane-A
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A 2 receptor antagonist.
1. A method of treating muscular dystrophy, comprising administering a therapeutically effective amount of a thromboxane A 2 receptor antagonist to a patient suffering from muscular dystrophy.
2. The method of claim 1 , wherein the muscular dystrophy is selected from the group consisting of Duchenne MD (DMD), Becker MD, and Limb-Girdle MD.
3. The method of claim 1 , further comprising administering the thromboxane A 2 antagonist to the patient on a chronic basis.
4. The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof.
5. The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
6. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered orally, intranasally, rectally, vaginally, sublingually, buccally, parenterally, or transdermally.
7. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered parenterally.
8. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered orally.
9. The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is administered prophylactically to prevent cardiomyopathy in the patient.
10. The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is administered prophylactically to prevent gastrointestinal dysfunction in the patient.
11. The method of claim 3 , wherein the therapeutically effective amount is from about 50 mg to about 500 mg, per day.
12. The method of claim 4 , wherein the therapeutically effective amount is from about 150 mg to about 350 mg per day and the ifetroban is administered orally.
13. A method of treating cardiac and/or gastrointestinal dysfunction in a human patient suffering from muscular dystrophy, comprising chronically administering a therapeutically effective amount of a thromboxane A 2 receptor antagonist to the human patient.
14. The method of claim 13 , wherein the therapeutically effective amount is from about 100 mg to about 500 mg, per day.
15. The method of claim 13 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof.
16. The method of claim 15 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
17. The method of claim 15 , wherein the therapeutically effective amount is from about, 150 mg to about 350 mg per day and the ifetroban is administered orally.
18. The method of claim 13 , wherein the gastrointestinal dysfunction is smooth muscle dysfunction.
19. A method of treating cardiac dysfunction in a human patient suffering from muscular dystrophy, comprising chronically administering a therapeutically effective amount of a thromboxane A 2 receptor antagonist to a human muscular dystrophy patient suffering from cardiac dysfunction.
20. The method of claim 19 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof.
21. The method of claim 19 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
22. The method of claim 19 , wherein the therapeutically effective amount is from about 50 mg to about 500 mg, per day.